MASHINIi

Addex Therapeutics Ltd.

ADXN.US | Manufacture of pharmaceuticals, medicinal chemical and botanical products

Addex Therapeutics Ltd is a biopharmaceutical company pioneering allosteric modulation-based drug discovery and development. The company focuses on developing novel, orally available small molecule allosteric modulators for neurological disorders. Their pipeline includes programs targeting specific ...Show More

Ethical Profile

Mixed.

Addex Therapeutics Ltd presents a mixed ethical profile. The company demonstrates a commitment to 'Better Health for All' by developing treatments for neurological disorders, including Parkinson's disease and addiction. Its lead program, Dipraglurant, has shown good safety and tolerability in Phase 2 data for levodopa-induced dyskinesia. Addex also secured a $5.3 million grant from NIDA to advance treatments for drug abuse and addiction. However, reports suggest Addex conducts pre-clinical studies involving animal testing, including non-human primates, with no public information available on alternative methods or animal welfare practices. Critics also point to a lack of data regarding drug price accessibility for vulnerable populations.

Value Scores

Better Health for All-10
-100100
Fair Money & Economic Opportunity0
-100100
Fair Pay & Worker Respect0
-100100
Fair Trade & Ethical Sourcing0
-100100
Honest & Fair Business0
-100100
Kind to Animals-70
-100100
No War, No Weapons0
-100100
Planet-Friendly Business0
-100100
Respect for Cultures & Communities0
-100100
Safe & Smart Tech0
-100100
Zero Waste & Sustainable Products0
-100100

Better Health for All

-10

Addex Therapeutics' entire business is devoted to developing treatments for neurological disorders and addiction, including Parkinson's disease levodopa-induced dyskinesia, dystonia, autism, and addiction to nicotine, cocaine, and alcohol. There is no evidence of revenue from products with negative health impacts. The company received a $5.3 million grant from the US National Institute on Drug Abuse (NIDA) in 2017 for human studies of ADX71441 for cocaine use disorder.

1
Addex also invested CHF 2 million in Stalicla, a company focused on neurodevelopmental and neuropsychiatric disorders, which has raised over $50 million in equity and over $30 million in non-dilutive funding.
2
Stalicla's STP7 program for cocaine use disorders is progressing towards Phase 3 trials with full US government funding.
3
The Johns Hopkins University ethics committee approved a receptor occupancy study for dipraglurant in 2015.
4

Fair Money & Economic Opportunity

0

Addex Therapeutics Ltd is a biopharmaceutical company focused on drug discovery and development for neurological disorders.

1
The company's core business does not involve lending, insuring, moving, or storing money for consumers.
2
Therefore, the provided articles do not contain any relevant information or data points to assess the company against the KPIs for 'Fair Money & Economic Opportunity', which are designed for financial institutions. All KPIs are omitted due to lack of applicable evidence.

Fair Pay & Worker Respect

0

Addex Therapeutics underwent a significant restructuring, resulting in the termination of 17 out of 19 employees.

1
The company's CEO, Dr. Bharatt Chowrira, also stepped down.
2
No other specific data regarding fair pay, worker respect, or safety metrics were provided in the article.
3

Fair Trade & Ethical Sourcing

0

No specific, concrete data points were found in the provided articles to assess Addex Therapeutics Ltd (ADXN.US) against the 'Fair Trade & Ethical Sourcing' value. explicitly states that it focuses on corporate governance and contains no quantitative data related to fair trade and ethical sourcing for ADXN.US.

1
Articles and pertain to 'Addtech' and its Supplier Code of Conduct, which is a different company and therefore not relevant to ADXN.US.
2

Honest & Fair Business

0

The provided articles state that the company has a Whistleblower Policy and an Anti-Corruption Policy.

1
However, no specific details regarding the strength, scope, enforcement, or effectiveness of these policies are provided.
2
For all other KPIs, no relevant information was found in the articles.
3

Kind to Animals

-70

Addex Therapeutics conducts pre-clinical studies on animals, including non-human primates, to assess drug safety and efficacy.

1
The company uses animal models for conditions such as Parkinson's disease and spasticity.
2
There is no formal animal testing policy stated in the provided articles.
3
The company has used non-human primates for PET studies
4
and for testing ADX48621.
5
While the Michael J. Fox Foundation, which funded a Phase II study for ADX48621, has invested almost $200 million in research to date,
6
there is no evidence that Addex Therapeutics itself participates in multi-stakeholder initiatives to develop industry-wide animal-free testing standards.

No War, No Weapons

0

The provided article discusses ADXN's Q1 2022 financial results but does not contain any information relevant to the 'No War, No Weapons' ethical value or its associated KPIs.

1
Therefore, no assessment can be made against the specified metrics.

Planet-Friendly Business

0

No specific, concrete data points related to planet-friendly business practices for Addex Therapeutics Ltd (ADXN.US) were found in the provided articles. Articles from addextherapeutics.com focus on patent, corporate governance, and financial information, explicitly stating no ESG or sustainability data. Articles from addtech.com, while incorrectly associated with the ADXN.US ticker in their summaries, pertain to a different company, Addtech, and therefore cannot be used as evidence for Addex Therapeutics Ltd.

1

Respect for Cultures & Communities

0

No evidence available to assess Addex Therapeutics Ltd on Respect for Cultures & Communities.

Safe & Smart Tech

0

No relevant evidence was found in the provided articles for ADXN.US (Addex Therapeutics Ltd). explicitly states that the privacy policy pertains to 'Addex Pharma SA' and is 'not ADXN.US', clarifying that it is 'a different company'.

1

Zero Waste & Sustainable Products

0

No evidence available to assess Addex Therapeutics Ltd on Zero Waste & Sustainable Products.

Own Addex Therapeutics Ltd?

Upload your portfolio and see how all your holdings score across 11 ethical dimensions.

Audit My Portfolio

AI-generated analysis based on publicly available data. Not financial advice. Ratings are expressions of opinion derived from automated models and may contain inaccuracies. See our Risk Disclosure for full details.